文献速递艾滋病与性传播感染

TAILoR研究:替米沙坦降低HIV感染者胰岛素抵抗的适应性设计IIb期随机试验

TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy.
PubMed 文献 · Clin Infect Dis · 2020-01-01

TAILoR是一项多中心、随机、开放标签、剂量探索的IIb期试验,评估替米沙坦对接受联合抗逆转录病毒治疗的HIV感染者胰岛素抵抗的影响。377例患者随机分配至对照组或替米沙坦20、40、80 mg组,主要终点为24周HOMA-IR变化。结果显示80 mg替米沙坦组与对照组HOMA-IR无显著差异(估计效应0.007,SE 0.106),部分次要终点有边缘改善。

要点

  • 替米沙坦80 mg未显著改善24周HOMA-IR。
  • QUICKI、hs-CRP及肝脂肪含量有边缘改善。
  • 该人群需探索预防心血管疾病的新策略。

核心结论

  • 替米沙坦对主要终点HOMA-IR无显著影响,但部分次要终点有边缘改善。

研究设计与样本

  • 多中心、随机、开放标签、剂量探索的适应性设计IIb期对照试验,共招募377例接受联合抗逆转录病毒治疗的HIV感染者。

主要发现

  • 24周时替米沙坦80 mg组与对照组HOMA-IR无差异(估计效应0.007,SE 0.106)。
  • 48周纵向分析显示HOMA-IR、血脂或脂肪因子水平无变化。

关键数值与推荐

  • 主要终点为24周HOMA-IR相对基线的变化。
  • 第一阶段随机分配至对照(48例)及替米沙坦20 mg(49例)、40 mg(47例)、80 mg(45例)组,共189例。
  • 中期分析后80 mg组进入第二阶段(对照105例,80 mg组106例)。

临床怎么用

  • 不推荐使用替米沙坦以改善接受抗逆转录病毒治疗HIV感染者的胰岛素抵抗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination antiretroviral therapy results in metabolic abnormalities which increase cardiovascular disease risk. We evaluated whether telmisartan reduces insulin resistance in human immunodeficiency virus (HIV)-positive individuals on antiretrovirals. METHODS: We conducted a multicenter, randomized, open-label, dose-ranging controlled trial of telmisartan. Participants with HIV infection receiving combination antiretroviral therapy were randomized equally to either no intervention (control) or 20, 40, or 80 mg telmisartan once daily. The adaptive design allowed testing of all dose(s) of telmisartan in stage I, with the promising dose(s) being taken into stage II. The primary outcome measure was reduction in homeostasis model assessment of insulin resistance (HOMA-IR) at 24 weeks. RESULTS: A total of 377 patients were recruited. In stage I, 48, 49, 47, and 45 patients were randomized to control and 20, 40, and 80 mg telmisartan, respectively (total n = 189). At the interim analysis, 80 mg telmisartan was taken forward into stage II. At the end of stage II (n = 105, control; 106, 80-mg arm), there were no differences in HOMA-IR (estimated effect, 0.007; SE, 0.106) at 24 weeks between the telmisartan (80 mg) and nonintervention arms. Longitudinal analysis over 48 weeks showed no change in HOMA-IR, lipid or adipokine levels. There were significant (P ≤ .05), but marginal, improvements in revised Quantitative Insulin Sensitivity Check Index (QUICKI) (0.004) and plasma hs-CRP (-0.222 mg/L) and reduction in liver fat content (1.714 mean reduction; P = .005). CONCLUSIONS: No significant effect of telmisartan was demonstrated on the primary outcome (HOMA-IR), but there were marginal improvements with some secondary outcome measures. Further studies in this population are warranted to identify novel strategies for preventing cardiovascular morbidity and mortality. CLINICAL TRIAL REGISTRATION: ISRCTN registry (51069819).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pushpakom S, Kolamunnage-Dona R, Taylor C, et al. TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clin Infect Dis. 2020. PMID: 31425580. doi:10.1093/cid/ciz589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。